Related Experiment Video
Updated: Aug 14, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Harnessing hormonal signaling for cardioprotection
Victoria L Ballard1, Jay M Edelberg
1Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
Insights
Estrogen may protect the heart, but hormone replacement therapy (HRT) risks are debated. Research seeks safer estrogen-based strategies for cardiovascular health in postmenopausal women.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Women's Health
Background:
- Cardiovascular disease (CVD) is a leading cause of death in Western women, particularly the elderly.
- Premenopausal women have lower CVD risk than men, suggesting a cardioprotective role for estrogen.
- Menopause is associated with increased cardiovascular risk, highlighting hormonal influences.
Purpose of the Study:
- To review the known cardiovascular actions of estrogen.
- To focus on estrogen's cardioprotective mechanisms.
- To identify targets for novel estrogen-based therapies for cardiovascular disease.
Main Methods:
- Review of existing scientific literature and clinical studies.
- Analysis of epidemiological data linking menopause and cardiovascular risk.
- Examination of findings from hormone replacement therapy (HRT) trials, including the Women's Health Initiative (WHI).
Main Results:
- Conflicting evidence exists regarding HRT's effect on cardiovascular events.
- While some studies suggest estrogen is cardioprotective, the WHI indicated potential increased risks.
- The link between menopause and higher cardiovascular risk remains evident despite HRT controversies.
Conclusions:
- Novel estrogen-based strategies are needed to leverage cardioprotective effects without vascular risks.
- Targeting specific estrogen actions may offer safer alternatives to current HRT.
- Further research is essential to develop effective, safe estrogen-based cardiovascular therapies for women.
Abstract:
Cardiovascular disease is the leading cause of death in women in the Western world and is predominant among the elderly. A large body of evidence suggests that hormonal signaling plays a critical role in the regulation of cardioprotective mechanisms, as premenopausal women are at significantly lower risk of heart disease compared with men, but the risk greatly increases with the onset of menopause. This association indicates that estrogen may protect the heart from cardiovascular disease. Whereas a number of analyses of the effects of hormone replacement therapy (HRT) on postmenopausal women supported the idea that estrogen is a cardioprotective factor, the findings of the more recent Women's Health Initiative (WHI) study suggested that HRT may actually increase the risk of cardiovascular events. These conflicting reports have left both patients and clinicians reluctant to continue using current HRT regimes. The WHI findings do not, however, negate the epidemiological link between menopause and increased cardiovascular risk. Hence, the identification of the specific actions of estrogen that promote cardioprotective pathways without enhancing deleterious vascular mechanisms may provide novel estrogen-based alternatives to current HRT strategies. In this Review, we outline the known actions of estrogen on the cardiovascular system, focusing on cardioprotective mechanisms that may be targeted for the development of new therapeutic approaches.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Hormonal Regulation
Endocrine Signaling

